Therapeutic Antibodies: Bench to Market

Webinar Series of the Chinese Antibody Society

Upcoming Webinar

Register today to reserve your seat

FREE FOR EVERYONE

Nanobodies are typically obtained by immunizing camels or alpacas, and their animal-derived components have potential safety risks in clinical applications. In recent years, Dr. Ying’s team has developed the research and development platform for fully human nanobodies based on fully human germline genes. The team found that, due to their small size, and high stability and uniform properties, this kind of antibodies can be nebulized efficiently to form droplets with a median particle size of less than 5 microns, and the physical and chemical properties and biological activities of the antibodies will not be affected after nebulization. At the webinar, Dr. Ying will introduce the design, structure, property and function of this kind of antibody by taking anti-COVID-19 fully humanized nanobodies as an example.


Sign in to Register

Recent Webinars

Sign in to view recordings

Challenges and Opportunities for Innovative Macromolecular Radiopharmaceutical Drugs

08/27/2022

Dr. Tao Xu

The research and development of Radionuclide-drug conjugates (RDCs) have been continued for decades. Since the approval of Novartis' Lutathera®️, more and more patients can benefit from a diversified diagnosis and treatment method. However, as a difficulty in the development of RDCs, the selection of precursor often affects the efficacy of …

Preclinical DMPK support for the discovery and development of biological drugs

07/30/2022

Dr. Aiqun Li

Unlike small molecules, the development of biological drugs does not require in vitro ADME (absorption, distribution, metabolism, and elimination) studies. Thus, people may not clear what DMPK can do to support the discovery and development of biologics. The ultimate goal for preclinical DMPK studies is to propose the proper doses …

ImmunoCytokine: The New Era of Cancer Immunotherapy

06/25/2022

Dr. Liusong Yin

Cancer Immunotherapy has gained great breakthroughs since the 21st century, and brought significant clinical benefits to a large number of patients. However, even for the broadly used PD1/L1 immunotherapy, the relatively low objective response rate (ORR), short progression-free survival (PFS) of patients, and drug resistance and recurrence especially for solid …

Recent advances in upstream process development and manufacturing for mAb production

05/28/2022

Dr. Jianlin (Jim) Xu

Continued process development for monoclonal antibody (mAb) for more efficient manufacturing schemes is required to meet ever increasing patient needs. Process development for most mAb manufacturing focuses on Chinese hamster ovary (CHO) cells, as this host is relatively mature and has a long history of producing products with demonstrated safety …

This web app is a Python Django project independently coded (frontend+backend+deployment on AWS) by Xin Yu (Github, LinkedIn) in her volunteer capacity at the Chinese Antibody Society. Contents are maintained by CAS IT team. If you're interested in participating in the future development of this web app, please submit a volunteer application and request an interview with the IT team. We require a minimum of 2 years experience as a Django developer. © Chinese Antibody Society 2021. All Rights Reserved. Legal Disclaimer
Icon